ÑÇÖÞ×ÔοÊÓƵ

Robert L. Dood
( out of 123 reviews )

Robert L. Dood, MD, MSCE

Languages spoken: English, Spanish

Clinical Locations

Sugar House ÑÇÖÞ×ÔοÊÓƵ Center

Salt Lake City
801-581-2000

  • Robert Dood, MD MSCE is a gynecologic oncologist and assistant professor at the ÑÇÖÞ×ÔοÊÓƵ of Utah School of Medicine and the Huntsman Cancer Institute. He specializes in the treatment of gynecologic pre-cancers and cancers of the ovary, uterus and endometrium, cervix, vulva, and vagina. His interests include screening and managing high risk and hereditary cancer populations including those with BRCA mutations and Lynch/HNPCC syndromes. He has a passion for fertility-sparing approaches in young women with cancer, pre-cancer, and hereditary syndromes, with special skills in hormonal approaches to endometrial cancer, uterus-sparing surgery for cervix cancer (trachelectomy), and sentinel lymph node evaluation of cervix and uterine cancers. His surgical expertise includes personalized approaches to cancer care, and minimally invasive approaches including both laparoscopic and robotic technologies.

    His research interests include implementing enhanced recovery after surgery (ERAS) protocols, optimizing clinical and surgical outcomes, efficient survivorship models, with methods in implementation science and big data.

    After completing his Bachelor of Science (BS) degree in Biochemistry from the ÑÇÖÞ×ÔοÊÓƵ of Michigan with High Distinction, he attended the Perelman School of Medicine at the ÑÇÖÞ×ÔοÊÓƵ of Pennsylvania where he received his Medical Doctorate (MD) and Master of Science in Clinical Epidemiology (MSCE) degrees. He completed his residency in Obstetrics and Gynecology at the Hospital of the ÑÇÖÞ×ÔοÊÓƵ of Pennsylvania, and his research and clinical fellowship in Gynecologic Oncology at the ÑÇÖÞ×ÔοÊÓƵ of Texas MD Anderson Cancer Center.

    Specialties

    Patient Rating

    4.9 /5
    ( out of 123 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 31, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr.Dood is fantastic! He made me feel comfortable, and it was very easy to develop a good rapport with him. He explained everything in detail, in a way that was easily understandable. I felt like I could trust him to provide me with the best care possible.

    October 29, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Dood is a thorough, respectful, knowledgeable, respectful provider.

    October 10, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr Dood is skilled, compassionate and thorough!

    October 10, 2024
    SUGAR HOUSE HEALTH CENTER

    I am so impressed with the care I have received by Dr Dood. He has been helpful and attentive, and gone to great lengths to make sure I understood each step of treatment. And he loves dragons!

    September 05, 2024
    SUGAR HOUSE HEALTH CENTER

    Very kind and thorough. Explained everything so I would understand.

    July 31, 2024
    HUNTSMAN CANCER CENTER

    Dr. Dood is the best Doctor I have ever had, I recommend if you need treatment for all girl cancer that you see him.

    July 18, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Dood is very nice and thorough. He explains everything good or bad and what to expect with all.

    July 12, 2024
    SUGAR HOUSE HEALTH CENTER

    I find Dr. Dood to be very kind and considerate.

    July 12, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Dood is very personable and caring. He provides excellent care. His explanation of my treatment plan and care is thorough and well thought out. His knowledge and attention to treatment planning as a physician is very reassuring. I have felt very confident in my treatment provided under his care. Thank you Dr. Dood for your excellent care both in my surgery and after care!!

    See More Patient Comments

  • Robert Dood, MD MSCE is a gynecologic oncologist and assistant professor at the ÑÇÖÞ×ÔοÊÓƵ of Utah School of Medicine and the Huntsman Cancer Institute. He specializes in the treatment of gynecologic pre-cancers and cancers of the ovary, uterus and endometrium, cervix, vulva, and vagina. His interests include screening and managing high risk and hereditary cancer populations including those with BRCA mutations and Lynch/HNPCC syndromes. He has a passion for fertility-sparing approaches in young women with cancer, pre-cancer, and hereditary syndromes, with special skills in hormonal approaches to endometrial cancer, uterus-sparing surgery for cervix cancer (trachelectomy), and sentinel lymph node evaluation of cervix and uterine cancers. His surgical expertise includes personalized approaches to cancer care, and minimally invasive approaches including both laparoscopic and robotic technologies.

    His research interests include implementing enhanced recovery after surgery (ERAS) protocols, optimizing clinical and surgical outcomes, efficient survivorship models, with methods in implementation science and big data.

    After completing his Bachelor of Science (BS) degree in Biochemistry from the ÑÇÖÞ×ÔοÊÓƵ of Michigan with High Distinction, he attended the Perelman School of Medicine at the ÑÇÖÞ×ÔοÊÓƵ of Pennsylvania where he received his Medical Doctorate (MD) and Master of Science in Clinical Epidemiology (MSCE) degrees. He completed his residency in Obstetrics and Gynecology at the Hospital of the ÑÇÖÞ×ÔοÊÓƵ of Pennsylvania, and his research and clinical fellowship in Gynecologic Oncology at the ÑÇÖÞ×ÔοÊÓƵ of Texas MD Anderson Cancer Center.

    Board Certification and Academic Information

    Academic Departments Obstetrics & Gynecology -Primary
    Academic Divisions Gynecological Oncology

    Selected Publications

    Journal Article

    1. Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA (2018). Defining Survivorship Trajectories Across Patients with Solid Tumors: An Evidence-Based Approach. JAMA Oncol, 4(11), 1519-1526. ()
    2. Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK (2018). When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer, 28(8), 1485-1490. ()
    3. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK (2018). Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 3(11). ()
    4. Huang Y, Hu W, Huang J, Shen F, Sun Y, Ivan C, Pradeep S, Dood R, Haemmerle M, Jiang D, Mangala LS, Noh K, Hansen JM, Dalton HJ, Previs RA, Nagaraja AS, McGuire M, Jennings NB, Broaddus R, Coleman RL, Sood AK (2017). Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther, 17(2), 464-473. ()
    5. Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK (2017). Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget, 8(57), 96496-96505. ()
    6. Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK (2017). Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun, 8(1), 310. ()
    7. Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK (2017). Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 2(16). ()
    8. Sans M, Gharpure K, Tibshirani R, Zhang J, Liang L, Liu J, Young JH, Dood RL, Sood AK, Eberlin LS (2017). Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Res, 77(11), 2903-2913. ()
    9. Dood RL, Gracia CR, Sammel MD, Haynes K, Senapati S, Strom BL (2014). Endometrial cancer after endometrial ablation vs medical management of abnormal uterine bleeding. J Minim Invasive Gynecol, 21(5), 744-52. ()

    Letter

    1. Dood RL (2014). Reply: To PMID 24590007. [Letter to the editor]. J Minim Invasive Gynecol, 22(3), 510. ()